Gilead Sciences Inc

GIS

Company Profile

  • Business description

    Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

  • Contact

    333 Lakeside Drive
    Foster CityCA94404
    USA

    T: +1 650 574-3000

    E: [email protected]

    https://www.gilead.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    17,600

Stocks News & Analysis

stocks

Another incredible quarter from Microsoft

We were wrong when we thought last quarter would be hard to top.
stocks

10 best US dividend aristocrats to buy now—including a surprise outperformer

These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks

Leading ASX players in this field look materially overvalued

We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,917.1081.90-0.91%
CAC 407,546.16225.81-2.91%
DAX 4023,425.97639.50-2.66%
Dow JONES (US)43,588.58542.40-1.23%
FTSE 1009,068.5864.23-0.70%
HKSE24,507.81265.52-1.07%
NASDAQ20,650.13472.31-2.24%
Nikkei 22540,799.60270.22-0.66%
NZX 50 Index12,729.4094.34-0.74%
S&P 5006,238.01101.38-1.60%
S&P/ASX 2008,662.0080.80-0.92%
SSE Composite Index3,559.9513.26-0.37%

Market Movers